Early API Momentum At Indian Firms: Not Just A Quarterly Bump?

Alembic and Biocon kick off the Q1 earnings season in India with significant growth in the active pharmaceutical ingredients business and expect to see continued momentum in the area. More Indian firms could gain as customers realign strategies and move away from single sources to de-risk their supply chain, learning from pandemic-related disruptions.

Business improvement (ImageFlow/Shutterstock.com) — API Sales Of Indian Firms Spurt In Q1 • Source: Shutterstock

The first-quarter fiscal 2021 earnings of India's Alembic Pharmaceuticals Limited and Biocon, Ltd. have reflected strong traction in the active pharmaceutical ingredients (APIs) business against the backdrop of coronavirus pandemic-related disruptions as customers stocked up to ensure business continuity.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

21 Apr 2025

• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

18 Apr 2025

• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

18 Apr 2025

• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.